Amarin reported $0 in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amarin USD 0 0 Mar/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
DBV Technologies USD 8.59M 295K Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 47B 11.62B Mar/2026